
<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>USP - Olmezest</title>
<style>
        * {
            box-sizing: border-box;
        }

        body {
            margin: 0;
            padding: 0;
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: #f4f6f8;
        }

        .container {
            background: #fff;
            max-width: 800px;
            margin: 20px auto;
            padding: 20px 25px;
            border-radius: 16px;
            box-shadow: 0 8px 24px rgba(0, 0, 0, 0.1);
        }

        h1 {
            background-color: #0D9A9F;
            color: #fff;
            padding: 12px 20px;
            border-radius: 8px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
            font-size: 24px;
            margin-bottom: 20px;
            text-align: center; /* Text center aligned */
        }

        ul {
            padding-left: 20px;
        }

        li {
            padding: 10px;
            margin-bottom: 10px;
            background: #ecf0f1;
            border-left: 5px solid #3498db;
            border-radius: 8px;
            color: #2c3e50;
            font-size: 16px;
            list-style: none;
            position: relative;
        }

        li::before {
            content: "✔";
            color: #27ae60;
            font-weight: bold;
            position: absolute;
            left: -20px;
            top: 12px;
        }

        @media (max-width: 600px) {
            .container {
                margin: 10px;
                padding: 15px 20px;
            }

            h1 {
                font-size: 20px;
            }

            li {
                font-size: 15px;
            }
        }
</style>
  </head>
<body>
    <div class="container">
	  <h1>USP- Olmezest</h1>
	  
	  

	  <h2>New Highlighting Points/ USPs:</h2>
	  <ul>
		<li>Significant and consistent 24 h BP reduction</li>
		<li>Faster onset of action – early lowering of BP within 2 weeks</li>
		<li>Simple dosing increases patient compliance</li>
		<li>Low dose combinations more effective than high dose monotherapy</li>
		<li>CCB synergistically enhances the inhibitory action of Olmesartan on brain ischemia</li>
	  </ul>
	  
	  <h2>Old Highlighting Points/ USPs:</h2>
	  
        <ul>
            <li>Reduces blood pressure within 1-2 weeks; binding affinity to AT1 receptor is 12500 fold.</li>
<li>Exhibits powerful BP reduction even during last 4 hours of 24-hour dosing period.</li>
<li>Reduces wall to lumen ratio up to 25% (VIOS Study) - provides cardiovascular protection beyond BP control.</li>
<li>Maintains powerful BP reduction for 24 hrs due to highest RASS blockade (2009 Journal).</li>
<li>Reduces SBP & DBP significantly more than Losartan, Valsartan, Irbesartan (OPARIL Trial).</li>
<li>23% risk reduction of microalbuminuria onset in type-2 diabetes (ROADMAP Trial).</li>
<li>Reduces vascular inflammation, lowers risk of CV events (EUTOPIA Study).</li>
<li>Reduces atherosclerotic plaque volume beyond BP control (MORE Study).</li>
<li>Bioavailability not reduced by food, unlike Losartan.</li>
<li>More patients achieved goal BP than Losartan or Valsartan.</li>
<li>AZTEC Study confirms Olmezest AM 40 ensures maximum BP reduction.</li>
        </ul>
    </div>
</body>
</html>
